ClinicalTrials.gg
Sign In
Drug

Rifampin clinical trials

Also written Rifampicin, Rifadin and Rimactane.

studies test it
161
open now
17
in phase 3
26
first study started
1994
Related medicines add 2 studies

Counted the way a researcher would: Rifampin with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Rifampin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Rifampin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 May 1971 · RIFADIN · NDA 050420 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Rifampin
57
RIF
9
Rifampicin (R)
4
Rifampin 600 mg
3
Rofact
3

Brand

Rifadin
16
Rimactane
4
RIMACTAN
2

Development codes

RIF10
1
RIF20
1
Rifa® 600
1

Other names

Rifampicin
57
Rifampicin 600 mg
1

In one entry with another drug

Given together, or one or the other

HRZE
2

Studies by the year they started

158 studies that test it; most in 2011 (15); 1 more planned to start later

Studies that test Rifampin, by start year
YearStudies
19941
20001
20022
20031
20042
20065
20074
20086
20096
20107
201115
20125
20139
201410
20158
20168
20178
20186
20197
202010
20216
202211
20236
20247
20254
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
67
Phase 2
29
Phase 3
26
Phase 4
24
No phase
17

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Tuberculosis
19
Tuberculosis, Pulmonary
16
Tuberculosis, Meningeal
6
HIV Infections
4
Latent Tuberculosis
4
Alzheimer Disease
3
Cystic Fibrosis
3
Endocarditis
2
Leprosy
2
Hematologic Neoplasms
2
Melanoma
2
Neoplasms
2

Who runs them

Industry 46 · Other 115

National Institute of Allergy and Infectious Diseases (NIAID) (7) · University of California, San Francisco (5) · University of Cape Town (4) · Johns Hopkins University (4) · University of Oulu (4) · Millennium Pharmaceuticals, Inc. (3) · Radboud University Medical Center (3) · Michael Hoelscher (3)

Often tested with

Tested in the same studies.

Isoniazid (30) · Pyrazinamide (20) · Ethambutol (19) · Itraconazole (15) · Levofloxacin (7) · Doxycycline (7) · Azithromycin (5) · Moxifloxacin (5)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 10 phase 3 studies under way

Rifampin is the comparator. A study of two new drugs counts under both.

  • 4Bedaquiline · Shenzhen Third People's Hospital, Centers for Disease Control and Prevention · next primary completion Dec 2026
  • 3Sitafloxacin · Shenzhen Third People's Hospital, First Affiliated Hospital of Zhejiang University · next primary completion Jan 2029
  • 3Rifapentine · First Affiliated Hospital of Zhejiang University, Johns Hopkins University · next primary completion Sep 2027
  • 2Rifabutin · Centers for Disease Control and Prevention, Tourcoing Hospital · next primary completion Nov 2026
  • 2Moxifloxacin · Centers for Disease Control and Prevention, Johns Hopkins University · next primary completion Dec 2026
  • 2Linezolid · Shenzhen Third People's Hospital · next primary completion Jan 2029
  • 2Pyrazinamide · First Affiliated Hospital of Zhejiang University, Shenzhen Third People's Hospital · next primary completion Jan 2029
  • 1OPC-67683 · Centers for Disease Control and Prevention · next primary completion Dec 2026
Reaching primary completion within a year · 5, 1 in phase 3

Studies that test Rifampin, phase 3 first.

Studies

Open first, then newest update. How each study uses Rifampin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 161

See all 161 studies that test Rifampin →

Given beside what is tested · 147 — Rifampin is usual care or a partner of the new treatment

Showing 20 of 147.

As the comparator · 47 — what is tested is compared with Rifampin

Showing 20 of 47.

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting1

Codes

What other systems call Rifampin · ClinicalTrials.gg INT008163

  • MeSH (NLM) D012293RifampinConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) VJT6J7R4TRRIFAMPINConfirmed FDA, NLM
  • RxNorm 9384One source FDA
  • NCI Thesaurus C811RifampinOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.